Navigation Links
Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
Date:6/8/2011

ns including a $1.0 billion merger between Corixa and Coulter.  Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development.  

Ms. Morris received her bachelor's degree in biology and chemistry from Carlow College. In addition to Syndax Ms. Morris serves on the board of directors of Neovacs, MediciNova and Humane Society of Silicon Valley.

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Syndax's lead product candidate is entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor with a long half-life that allows for weekly or every-other-week dosing. The robust clinical program for entinostat includes: a randomized, phase 2 clinical trial in patients with advanced non-small cell lung cancer that showed a survival advantage in a subset of the population, a completed randomized, placebo-controlled phase 2 trial in advanced breast cancer that will be presented later this year, nine ongoing trials in various cancers including advanced breast, non-small-cell lung cancer and  colorectal cancer and a pivotal program that is being planned for women with advanced metastatic estrogen-receptor positive breast cancer.  Formed in 2005 the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.  Syndax has worldwide rights to develop and commercialize entinostat and is backed by top-
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
3. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
4. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
5. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
6. Syndax Pharmaceuticals to Present at Biotech Showcase 2011
7. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
8. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DALLAS , September 22, 2014 ... report "Cell Line Development Market by Product (Equipment, Media ... (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, ... to 2019", published by MarketsandMarkets, analyzes and studies ... Browse 114 market data tables ...
(Date:9/22/2014)... 2014 CytRx Corporation (Nasdaq: CYTR ... oncology, today announced that study designs and progress from ... a pivotal global Phase 3 clinical trial in relapsed/refractory ... clinical trial in small cell lung cancer, will be ... 2014 Congress being held September 26-30, in ...
(Date:9/19/2014)... Sept. 19, 2014 Harwood Feffer LLP ( ... of directors of PDL BioPharma, Inc. ("PDL" or the ... board has breached its fiduciary duties to shareholders or ... 16, 2014, the Company disclosed: "On September 11, 2014, ... firm, Ernst & Young LLP ("EY"), that it was ...
Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... Feb. 23, 2011 Plexus Biomedical Inc. has been ... and Drug Administration to market the first device clinically ... Hemorrhoids associated with vaginal delivery are a frequent complication ... women in the U.S. every year. The ...
... Inc. (Nasdaq: MAPP ) today announced that the ... Citi,s 2011 Global Healthcare Conference , Wednesday, March 2, at ... , Thursday, March 3, at 10:00 a.m. ET in ... March 9, at 10:15 a.m. ET in BostonBarclays Capital 2011 ...
Cached Medicine Technology:Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth 2
(Date:9/22/2014)... 2014 Don Allred Insurance is pleased to ... Burlington, NC. The satellite office, located in the Holly Hill ... 15, 2014, and offer all of the same professional services ... Allred Insurance spokesperson Scott Allred cites an expanding client base ... two of the major factors driving the decision to open ...
(Date:9/22/2014)... 22, 2014 Ethane Web Technologies, an ... to have announced affordable website redesign. The website redesign ... which are unsatisfied with their present websites and want ... to pay a big amount for this job. ... advanced tool, techniques, and experienced manpower so that it ...
(Date:9/22/2014)... Colorado's grand experiment with legal recreational marijuana for adults ... revenue for the state. , According to the ... was sold in Colorado dispensaries during the first five ... , But the success of these retail shops has ... the thousands of consumers now seeking out cannabis dispensaries ...
(Date:9/22/2014)... Available research evidence supports the use of deep ... who don,t respond to other treatments, concludes a review ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... specific bilateral DBS techniques are recommended for treatment of ...
(Date:9/22/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... GLOBAL MARKETS, the global market for autoimmune disease ... billion by 2019, with a five-year compound annual ... holds the highest market potential due to an ... western lifestyles. , In recent decades, autoimmune ...
Breaking Medicine News(10 mins):Health News:Allred Insurance to Open New Burlington Branch Office 2Health News:Ethane Web Technologies Announces Affordable Website Redesign Service 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 3Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 2Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 3Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3
... known about anticancer benefits of supplements, researchers caution , SUNDAY, ... may do nothing to protect men against bladder cancer and ... , In one study examining vitamin use, researchers analyzed more ... part in prostate screenings. , More than 60 percent ...
... 30 (HealthDay News) -- A study in mice suggests that ... scientists say. , Women may begin taking part in the ... added. , "We believe that this vaccine will someday be ... same way that vaccines have prevented many childhood diseases," principal ...
... just how sticking needles into the body can ease pain. ... Nature Neuroscience, a team at the University of Rochester ... in parlaying some of the effects of acupuncture in the ... the beneficial effects of acupuncture in mice by adding a ...
... ... $125 or more by FedEx Ground service to the 48 contiguous states in acknowledgment of ... allergy products company in the country, with over 10,000 referring doctors and 22 years of ... ...
... ... , ... Insurance Services, LLC ( HCCMIS ), is now utilizing CMN for health-care provider network administration in ...   Larger worldwide network directory with 400,000+ doctors and 7,000+ ...
... shallow or unfamiliar waters, experts say , SATURDAY, May 29 ... 14 are hospitalized each year because of a diving injury, ... spinal cord injury, researchers say. , To encourage diver safety, ... near any body of water and to jump feet first ...
Cached Medicine News:Health News:Vitamins Fail to Protect Men Against Bladder Cancer 2Health News:Acupuncture's molecular effects pinned down 2Health News:National Allergy Supply Announces Free Ground Shipping For Its Customers 2Health News:HCC Medical Insurance Services Chooses CMN as Network Administrator 2Health News:Dive Safely -- Or Risk Spinal Cord Damage 2
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Cushing periosteal elevators, rounded edge, sharp, wide, blade width 5/8" (16 mm), length 7 1/4" (184 mm)....
Barr periosteal elevators....
Molt 9 periosteal elevators....
Medicine Products: